This phase II trial tests how well nivolumab in combination with chemotherapy drugs along with radiation therapy works in treating patients with nasopharyngeal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.

开始日期2025-01-17

申办/合作机构

National Cancer Institute

NCT06050252 / Recruiting临床2期IIT

A Phase II Trial of Durvalumab With Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab with gemcitabine and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed in patients with high risk resectable cholangiocarcinoma.

开始日期2024-11-26

申办/合作机构

National Cancer Institute

NCT06029270 / Recruiting临床2期IIT

A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells grow or spread longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.

开始日期2024-10-04

申办/合作机构

National Cancer Institute

100 项与吉西他滨相关的临床结果

登录后查看更多信息

100 项与吉西他滨相关的转化医学

登录后查看更多信息

100 项与吉西他滨相关的专利（医药）

登录后查看更多信息

18,872

项与吉西他滨相关的文献（医药）

2024-12-31·Annals of Medicine

Advances in targeted therapy of cholangiocarcinoma

Review

作者: Peng, Chuang ; Liu, Sulai ; Song, Yinghui ; Yu, Jianfeng ; Zhang, Yujing ; Li, Yuhang

Cholangiocarcinoma (CCA) is a malignant tumor originating in the bile duct and its branching epithelium. Due to its high heterogeneity, there are no specific clinical indications at the early stage, the diagnosis is often in advanced CCA. With surgical resection, the 5-year postoperative survival rate (long-term survival rate) is very poor. The regimen of gemcitabine combined with platinum has been used as the first-line chemotherapy for advanced patients. In recent years, targeted therapy for a variety of malignant tumors has made great progress, showing good efficacy and safety in advanced CCA. However, the current targeted therapy of CCA still has many challenges, such as adverse reactions, drug resistance, and individual differences. Therefore, the researches need to further explore the targeted therapy mechanism of CCA malignancies in depth, develop more effective and safe drugs, and accurately formulate plans based on patient characteristics to further improve patient prognosis in the future. This article reviews the recent progress of targeted therapy for CCA, aiming to provide a strategy for the research and clinical work of targeted therapy for CCA.

2024-12-31·International Journal of Hyperthermia

Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model

Article

作者: Chen, Guoyi ; Chen, Wanyi ; Yu, Jie ; Ye, Zhangqun ; Xu, Ying ; Li, Huaibiao ; Liu, Chunyan ; Luo, Wanru ; Zhang, Huiping ; Zhao, Kai ; Liu, Haoran ; Hu, Poyi ; Sun, Guoliang ; Wu, Yuqing ; Zhang, Tingke ; Yang, Tiantian

OBJECTIVEThis study aimed to evaluate the combined efficacy of hyperthermia and chemotherapy using a bladder cancer organoid model and to explore hyperthermia-related molecular pathways.METHODTumor organoids were generated by embedding RT4 bladder cancer cells into Matrigel. The resulting organoids were treated with pirarubicin or gemcitabine at 37 °C or 42 °C. Proliferation was determined by Ki67 immunofluorescence staining, and apoptosis was assessed using a TdT-mediated dUTP nick end labeling (TUNEL) assay. RNA sequencing was used to identify the differentially expressed genes.RESULTSBladder cancer organoids were successfully established and exhibited robust proliferative abilities. Treatment with gemcitabine or pirarubicin under hyperthermic conditions caused pronounced structural damage to the organoids and increased cell death compared to that in the normothermically treated group. Furthermore, Ki67 labeling and TUNEL assays showed that the hyperthermia chemotherapy group showed a significantly reduced proliferation rate and high level of apoptosis. Finally, RNA sequencing revealed the IFN-γ signaling pathway to be associated with hyperthermia.CONCLUSIONOverall, hyperthermia combined with chemotherapy exerted better therapeutic effects than those of normothermic chemotherapy in grade 1-2 non-muscle-invasive bladder cancer, potentially through activation of the IFN-γ-JAK-STAT pathway.

2024-06-17·Nanotechnology

Novel silicene-mesoporous silica nanoparticles conjugated gemcitabine induced cellular apoptosis via upregulating NF-κB p65 nuclear translocation suppresses pancreatic cancer growth in vitro and in vivo

Article

作者: Chen, Yuhang ; Chen, Lianyu ; Dong, Shu ; Yang, Peiwen ; Cheng, Chien-Shan

AbstractPancreatic cancer’s high fatality rates stem from its resistance to systemic drug delivery and aggressive metastasis, limiting the efficacy of conventional treatments. In this study, two-dimensional ultrathin silicene nanosheets were initially synthesized and near-infrared-responsive two-dimensional silicene-mesoporous silica nanoparticles (SMSNs) were successfully constructed to load the clinically-approved conventional pancreatic cancer chemotherapeutic drug gemcitabine. Experiments on nanoparticle characterization show that they have excellent photothermal conversion ability and stability. Then silicene-mesoporous silica nanoparticles loaded with gemcitabine nanoparticles (SMSN@G NPs) were employed in localized photothermal therapy to control pancreatic tumor growth and achieve therapeutic effects. Our research confirmed the functionality of SMSN@G NPs through immunoblotting and apoptotic assays, demonstrating its capacity to enhance the nuclear translocation of the NF-κB p65, further affect the protein levels of apoptosis-related genes, induce the apoptosis of tumor cells, and ultimately inhibit the growth of the tumor. Additionally, the study assessed the inhibitory role of SMSN@G NPs on pancreatic neoplasm growth in vivo, revealing its excellent biocompatibility. SMSN@G NPs have a nice application prospect for anti-pancreatic tumors.

1,218

项与吉西他滨相关的新闻（医药）

2024-05-14

·CPHI制药在线

新药 | 复发或转移性鼻咽癌治疗浅谈，多款免疫疗法已入围

关注并星标CPHI制药在线近日，科伦博泰1类新药「塔戈利单抗注射液」的上市申请获CDE受理。据公开资料，塔戈利单抗(研发代号：KL-A167)是科伦博泰自主研发的PD-L1靶向人源化单抗，2021年其用于治疗既往接受过二线及以上化疗失败的复发或转移性鼻咽癌的上市申请获CDE受理，相关受理号为：CXSS2101052。根据KL-A167在国内登记的临床试验情况，笔者推测此次KL-A167申报的适应症为：联合GP（吉西他滨+顺铂）一线治疗复发或转移性鼻咽癌。鼻咽癌治疗现状鼻咽癌是一种原发于鼻咽部黏膜上皮的恶性肿瘤，其恶性程度高，呈浸润性生长。由于好发于咽隐窝、侧壁、鼻咽顶壁等隐蔽部位，且发病早期无特异性症状，鼻咽癌早期不易被诊断，超70%的鼻咽癌患者一经确诊即为局部晚期疾病。据国家癌症中心发布的《2022年中国恶性肿瘤疾病负担情况》，2022年全国鼻咽癌新发病例5.1万人，死亡病例2.84万人。远端转移和（或）复发是目前鼻咽癌面临的巨大挑战，此类患者预后较差。吉西他滨联合顺铂（GP）化疗方案是复发或转移性鼻咽癌患者的一线标准治疗方案，但疗效有限，中位无进展生存期（PFS）仅7个月左右，5年总体生存率小于20%。随着免疫疗法的进展，复发或转移性鼻咽癌患者的治疗也迎来了新选择，目前已有多款免疫抑制剂被批准用于治疗复发或转移性鼻咽癌，详见下表。值得国民骄傲的是，这四款药物均由国内药企自主研发，主要被批准用于复发或转移性鼻咽癌的一线和三线及以上治疗。这种局面可能与鼻咽癌在国内高发有很大关系，据悉2020年全球鼻咽癌新发病例数超13万，其中近半数病例在中国。具体品种来看，特瑞普利单抗和卡瑞利珠单抗被批准用于复发或转移性鼻咽癌的一线和三线及以上治疗，替雷利珠单抗被批准用于复发或转移性鼻咽癌的一线治疗，派安普利单抗被批准用于复发或转移性鼻咽癌的三线治疗，而且派安普利单抗联合化疗一线治疗转移鼻咽癌的新适应症上市申请已于2023年12月获CDE受理。值得一提的是，除了联合化疗，PD-1单抗还被开发联合其它药物用于治疗复发或转移性鼻咽癌，如派安普利单抗被开发联合TIM3单抗TQB2618治疗复发或转移性鼻咽癌。掘金复发或转移性鼻咽癌市场多款新疗法在研除了上述药物，目前国内还有几款免疫新疗法被开发用于治疗复发或转移性鼻咽癌。智翔金泰的PD-L1单抗GR1405联合GP化疗方案一线治疗复发或转移性鼻咽癌的临床试验已进入3期阶段，但鉴于国内PD-1/L1单抗市场竞争太过激烈，该药已终止开发。齐鲁制药的QL1706是利用MabPair技术平台产生的一款PD-1/CTLA-4靶向组合抗体，在单个细胞中以约2:1的比例同时生产2个工程化单克隆抗体，PD-1 IgG4抗体艾帕洛利单抗和CTLA-4 IgG1抗体托沃瑞利单抗。Journal of Hematology&Oncology杂志（IF=23.168）上发表的QL1706的首次人体大型I期临床研究结果证实：经优化和改造后的QL1706不良事件发生率明显降低，耐受性良好，且在NSCLC、鼻咽癌、宫颈癌等多个瘤种中均显示出良好的抗肿瘤活性。目前，该药正在进行一项头对头2/3期临床研究，旨在比较其与卡瑞利珠单抗分别联合吉西他滨和顺铂一线治疗复发或转移性鼻咽癌的有效性和安全性。正大天晴的TQB2618和信达生物的IBI310均作用于免疫疗法新靶点，其中TQB2618被开发联合派安普利单抗治疗复发或转移性鼻咽癌，IBI310被开发联合信迪利单抗治疗复发或转移性鼻咽癌。除了免疫疗法，复发或转移性鼻咽癌治疗领域还有几款在研新药，其中乐普生物的MRG003是国内首创的EGFR ADC，其针对既往经至少二线系统化疗（包括含铂化疗）和PD-1（L1）治疗失败的复发/转移性鼻咽癌的适应症被CDE纳入突破性治疗品种。已公布的MRG003治疗鼻咽癌的2a期临床研究数据显示：针对经PD-1/PD-L1及含铂化疗治疗的鼻咽癌患者，ORR为47.4%。2.0mg/kg剂量组的ORR为39.2%，mPFS为7.3个月；2.3mg/kg剂量组的ORR为55.2%。百利天恒的BL-B01D1是其自主研发的EGFR、HER3双靶向ADC，单药在多个上皮肿瘤适应症中均表现出强烈的疗效信号，目前其单药治疗末线鼻咽癌、二线食管鳞癌的临床研究已进3期研究阶段。2024年4月，BL-B01D1被CDE纳入突破性治疗品种，用于既往经PD-1/PD-L1单抗治疗且经至少两线化疗（至少一线含铂）治疗失败的复发性或转移性鼻咽癌患者。百吉生物的BRG01是一款针对EB病毒（EBV）的特异性CAR-T细胞疗法。在临床前研究中，BRG01被证明可以有效且特异性地清除包括鼻咽癌在内的多种gp350+肿瘤。2023年7月，该疗法被FDA授予治疗复发/转移性鼻咽癌的快速通道资格。总结鼻咽癌是我国发病率较高的一种恶性肿瘤，随着免疫疗法的发展，我国药企研发的多款PD-1单抗被批准用于复发或转移性鼻咽癌的一线和三线及以上治疗。与常见的乳腺癌、NSCLC治疗相比，复发或转移性鼻咽癌治疗领域还存在巨大未满足的市场需求。不过，目前国内还有多款在研复发或转移性鼻咽癌新疗法，且不仅限于免疫疗法。而且，免疫疗法在复发或转移性鼻咽癌治疗方面，除了联合化疗，还有更多的组合方式，如联合TIM-3、CTLA-4靶向单抗。期待在科研人员的不断探索下，复发或转移性鼻咽癌治疗迎来更多突破。【智药研习社近期线下课程预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

免疫疗法申请上市临床3期临床申请

2024-05-14

·CPHI制药在线

广谱抗癌药“杀”回中国，市场格局早已沧海桑田

关注并星标CPHI制药在线 2023年5月10日，国家药监局发布公告，恢复进口、销售、使用BMS子公司新基制药（Celgene Corporation）的白蛋白注射用紫杉醇（Abraxane）。这是自2020年宣布暂停进口后，首次对BMS这款原研药的"解禁"。不过四年过去，国内已有多款仿制药上市，白蛋白紫杉醇的市场格局早已沧海桑田。BMS归来，将如何突围？紫杉醇药物发展简史紫杉醇是一种红豆杉中提取的天然产物，通过作用于微管蛋白，抑制肿瘤细胞有丝分裂，是最重要的广谱化疗药物之一。自从20世纪60年代首次被发现后，紫杉醇便以注射剂的形式出现在市场。 1992年，FDA批准了第一款紫杉醇注射液，商品名为泰素（Taxol），用于治疗晚期卵巢癌，之后，又被批准用于治疗乳腺癌、非小细胞肺癌、卡波西肉瘤等癌种。然而由于紫杉醇水溶性差，需要借助于聚氧乙基代蓖麻油与无水乙醇的复合溶媒以提高溶解性，这类溶剂很容易刺激机体释放组胺，导致严重过敏。所以，在用药之前，患者通常需要皮质激素及抗组胺药的预处理，以减轻过敏反应，给药方案复杂。于是，一种叫做白蛋白结合型紫杉醇（Abraxane）的新一代紫杉醇药物应运而生。Abraxane利用人源白蛋白作为载体，可直接给药，无需用药前皮质激素和抗组胺药的预处理。 Abraxane由美国Abraxis公司开发，于2005年1月被FDA批准上市，用于治疗乳腺癌，商品名为Abraxane，随后又获批治疗肺癌、胰腺癌等。 2010年，新基以29亿美元首付款收购Abraxis，获得Abraxane。自上市以来，Abraxane的销售额一直处于较快增长态势。 2013年，Abraxane在中国获批上市。2017年，百济神州获得了这款药物的中国市场销售权。米内网数据显示，2018年，Abraxane公立医院销售额7.21亿元，远超其他同类产品。白蛋白紫杉醇进口禁令风波随着Abraxane专利到期，国内一众仿制药纷纷上市。2018年2月，石药集团的白蛋白结合型紫杉醇（克艾力）获批上市；2018年8月，恒瑞医药的艾越获批上市；2019年11月，齐鲁制药的齐鲁锐贝也获批上市。 2020年，在第二轮全国带量采购中，新基以1150元/100ml中标，供应省份涵盖北京、天津、浙江、湖北等。其余两家中标企业为石药欧意（747元/100ml）和恒瑞医药（780元/100ml）。然而在Abraxane中选不久，国家药监局在对BMS旗下位于美国伊利诺州的委托生产现场进行检查时，发现用于白蛋白结合型紫杉醇生产的部分关键生产设施不符合中国药品生产质量管理的基本要求，存在生产过程无菌控制措施不到位等问题，不符合我国《药品生产质量管理规范（2010年修订）》要求。因此依法暂停了Abraxane在中国的进口、销售和使用。随后，BMS在中国市场启动了Abraxane召回。在替补供应方面，2020年3月27日，国家联采办发布《关于确定部分地区注射用紫杉醇（白蛋白结合型）替补供应企业的通知》，确定由石药欧意和恒瑞医药作为原新基供应地区的替补供应企业。这意味着，石药欧意、恒瑞医药将瓜分国内30个省区70%的承诺采购量。去年8月，百济神州宣布与新基和解并终止3款成熟产品商业化合作。至此，Abraxane的中国权益全部归还BMS。紫杉醇市场格局生变，联用方案求破局截至目前，国内已有7家企业获得了注射用紫杉醇（白蛋白结合型）生产批文，包括石药集团、恒瑞医药、齐鲁制药、科伦药业、海正药业、康禾生物、海昶生物。为了应对仿制药的竞争，布局企业开始探索白蛋白紫杉醇与PD-1联用方案。2021年12月，恒瑞的PD-1单抗卡瑞利珠单抗联合白蛋白紫杉醇治疗晚期鳞状非小细胞肺癌和食管鳞癌一线治疗两大新适应症获NMPA批准；信达的信迪利单抗联合白蛋白紫杉醇正在进行针对复发性宫颈癌治疗的研究；复宏汉霖的斯鲁利单抗获批与白蛋白紫杉醇联合用于一线治疗局部晚期或转移性鳞状非小细胞肺癌的适应症。目前国内白蛋白紫杉醇竞争已趋于白热化，再次归来的Abraxane，要想重回以前的市场地位，必须从多方面进行改革。参考来源： 1.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16. PMID: 24131140; PMCID: PMC4631139. 2.https://clinicaltrials.gov/study/NCT02017015?locStr=China&country=China&distance=50&term=Abraxane&aggFilters=phase:2,status:com&cond=Pancreatic%20Cancer&rank=1.【智药研习社近期线下课程预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

专利到期并购

2024-05-14

·医药观澜

和黄医药与恒瑞医药达成合作，开发胰腺癌联合疗法

5月14日，和黄医药宣布启动一项中国2/3期临床试验，以评估和黄医药的候选药物索凡替尼、恒瑞医药的PD-1抗体卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨的联合疗法用于一线治疗转移性胰腺导管腺癌（PDAC）患者。首名受试者已于2024年5月8日接受首次给药治疗。胰腺导管腺癌是一种高度侵袭性的癌症，占胰腺癌的90%以上。常见的治疗方法包括化疗、手术和放疗，但患者的治疗效果并未显示出显著的改善，仅有不到20%的转移性胰腺癌患者能够存活超过一年。索凡替尼是一种新型的口服小分子激酶抑制剂，具有抗血管生成和免疫调节双重活性。索凡替尼可通过抑制血管内皮生长因子受体（VEGFR）和成纤维细胞生长因子受体(FGFR)以阻断肿瘤血管生成，并可抑制集落刺激因子-1受体（CSF-1R），通过调节肿瘤相关巨噬细胞，促进机体对肿瘤细胞的免疫应答。卡瑞利珠单抗（SHR-1210）是一种针对程序性死亡1（PD-1）受体的人源化单克隆抗体，目前已在全球同时开展十余项针对多种肿瘤和治疗情况的临床试验。在中国，卡瑞利珠单抗已获批9个适应症，包括肝细胞癌（二线和一线）、复发/难治性经典型霍奇金淋巴瘤（三线）、食管鳞癌（二线）和鼻咽癌（三线或以上），以及与化疗联用用于一线治疗非小细胞肺癌(非鳞状及鳞状)、食管鳞癌和鼻咽癌。本次启动的是一项多中心、随机、开放标签、阳性对照的2/3期试验，旨在评估索凡替尼联合卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨对比白蛋白结合型紫杉醇和吉西他滨在既往未接受过全身性抗肿瘤治疗的成人转移性胰脏癌患者中的疗效和安全性。在最初的安全性导入阶段之后，在研究的2/3期阶段或将额外招募500名患者，主要终点是总生存期（OS）。其他终点包括客观缓解率（ORR）、无进展生存期（PFS）、疾病控制率（DCR）、安全性、生活质量、缓解持续时间和到达疾病缓解的时间。和黄医药首席执行官兼首席科学官苏慰国博士表示：“包括来自ASCO胃肠癌研讨会上发表的一项研究者发起的临床试验在内的新数据表明，与现有基于化疗的转移性胰腺导管腺癌治疗相比，索凡替尼、卡瑞利珠单抗和化疗的联合疗法具有良好的疗效。我们希望这项合作将为患者带来有望改变生活的创新治疗选择。” 参考资料： [1] 和黄医药宣布与恒瑞医药达成合作并启动索凡替尼联合卡瑞利珠单抗用于治疗初治胰腺导管腺癌的II/III期研究. Retrieved May 14，2024, From https://mp.weixin.qq.com/s/US5D6xPphcvnx38jN_QuUA [2] Sarantis P et al. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173-181. DOI:10.4251/wjgo.v12.i2.173 [3] Jia R et al.Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC). JCO 42, 671-671(2024). DOI:10.1200/JCO.2024.42.3_suppl.671 内容来源于网络，如有侵权，请联系删除。

ASCO会议临床结果申请上市

100 项与吉西他滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02368	-	-	DB00441

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床3期	-	RenovoRx, Inc.	2023-06-01
转移性胰腺导管腺癌	临床3期	澳大利亚	Panbela Therapeutics, Inc.	2022-08-04
局部晚期胰腺腺癌	临床2期	美国	RenovoRx, Inc.	2018-03-12
晚期三阴性乳腺癌	临床2期	中国	复旦大学	2011-01-01
非小细胞肺癌	临床2期	新加坡	National University Hospital	2006-10-01
晚期非小细胞肺癌	临床2期	意大利	Sanofi	2005-05-01
难治性恶性生殖细胞肿瘤	临床2期	美国	Sanofi	2004-11-01
局部晚期胰腺腺癌	临床1期	比利时	RenovoRx, Inc.	2018-03-12
非小细胞肺癌IIIB期	临床1期	中国	新疆医科大学	2013-12-01
乳腺癌	临床前	新加坡	National University Hospital	2006-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NEWS 人工标引	临床2期	胰腺癌	-	Antroquinonol+白蛋白结合型紫杉醇+吉西他滨	(鏇網觸廠廠糧簾襯簾製) = 壓鬱獵夢淵繭鬱範網顧醖獵遞築築淵襯蓋夢憲 (衊獵顧觸製範選夢築範 ) 更多	积极	2024-01-19
				白蛋白结合型紫杉醇+吉西他滨	(鏇網觸廠廠糧簾襯簾製) = 淵選網襯膚齋積膚鹹膚醖獵遞築築淵襯蓋夢憲 (衊獵顧觸製範選夢築範 ) 更多
NCT04570410 (ASCO_GU2024) 人工标引	临床2期	膀胱癌新辅助	14	Tislelizumab + Gemcitabine + Cisplatin	(鏇廠鏇廠鹹餘衊壓膚壓) = 觸選遞選膚願餘齋積廠築鏇襯鬱鏇蓋遞艱齋繭 (構遞鏇積壓鬱糧窪襯顧 ) 更多	积极	2024-01-25
NCT02177695 (S1314-COXEN, ASCO_GU2024) 人工标引	临床2期	肌层浸润性膀胱癌新辅助	180	gemcitabine+cisplatin or methotrexate+vinblastine+adriamycin+doxorubicin+cisplatin	(繭鑰齋製觸廠構範願獵) = 醖鑰襯艱衊遞憲窪衊選艱鹽積窪艱壓鏇獵膚壓 (膚淵淵築願築遞築選觸 )	积极	2024-01-25
ASCO_GI2024 人工标引	N/A	Vater壶腹癌辅助	81	5-FU or gemcitabine	(鬱鹽餘鹽襯醖築觸網範) = 簾蓋醖艱選願範範壓遞顧顧鹹網鹹襯選襯築醖 (網構遞鹽築範範選膚遞 )	不佳	2024-01-18
NCT02564146 (AIO-PAK-0114（ALPACA ）, ASCO_GI2024) 人工标引	临床2期	胰腺癌一线	325	Gemcitabine+nab-paclitaxel (alternating treatment arm)	(鹽選鬱壓顧簾糧糧積淵) = 餘製顧壓繭淵醖餘憲艱遞製築窪鹹獵壓製觸淵 (簾範築齋膚蓋憲鑰憲淵 ) 更多	积极	2024-01-18
				Gemcitabine+nab-paclitaxel (standard treatment arm)	(鹽選鬱壓顧簾糧糧積淵) = 願膚蓋齋壓壓觸憲鹹積遞製築窪鹹獵壓製觸淵 (簾範築齋膚蓋憲鑰憲淵 ) 更多
NCT04099589 (ASCO_GU2024) 人工标引	临床2期	肾盂和输尿管尿路上皮癌新辅助	15	Gemcitabine+Cisplatin +Toripalimab	(範鏇憲範範觸襯積憲願) = 獵製繭廠醖鹽獵積願築鏇壓淵襯獵夢鹹觸齋鑰 (築膚糧膚醖獵壓積遞夢 ) 更多	积极	2024-01-25
NCT02650804 (Biospace) 人工标引	临床2期	胰腺癌二线 \| 三线	19	BPM31510+gemcitabine	(鑰窪蓋艱築鬱鹹鬱糧淵) = 觸範選壓積鬱廠觸製齋鹽齋積蓋觸鬱顧獵顧鹽 (鑰餘壓鹽夢簾艱齋遞製 )	积极	2024-01-18
				Gemcitabine	(鑰窪蓋艱築鬱鹹鬱糧淵) = 積鑰鑰鑰鏇製醖鬱積遞鹽齋積蓋觸鬱顧獵顧鹽 (鑰餘壓鹽夢簾艱齋遞製 )
UMIN000012720 (GENESECT, ASCO_GI2024) 人工标引	N/A	胰腺癌	50	gemcitabine (ABCC5 1146A>G)	(醖艱齋顧艱觸夢獵願壓) = 網醖遞簾顧鏇繭醖網鹽蓋齋繭蓋繭蓋廠鹽鹹顧 (遞簾繭繭築鹹繭鏇觸選 )	积极	2024-01-18
				gemcitabine (AG/GG)	(醖艱齋顧艱觸夢獵願壓) = 艱糧窪遞遞鑰淵襯鬱淵蓋齋繭蓋繭蓋廠鹽鹹顧 (遞簾繭繭築鹹繭鏇觸選 )
NCT04223856 (EV-302, Literature) 人工标引	临床3期	尿路上皮癌一线	886	Enfortumab vedotin + Pembrolizumab	(鹽夢選糧鬱艱齋構鬱範) = 糧鹹鬱鏇廠網憲鏇製齋窪觸餘壓製網齋遞獵積 (簾鑰繭壓齋遞蓋網襯製 ) 更多	积极	2024-03-07
				Gemcitabine + Cisplatin/Carboplatin	(鹽夢選糧鬱艱齋構鬱範) = 夢齋夢壓鹹構鹽憲憲築窪觸餘壓製網齋遞獵積 (簾鑰繭壓齋遞蓋網襯製 ) 更多
ChiCTR2100050763 (ASCO_GU2024) 人工标引	临床2期	肌层浸润性膀胱癌新辅助	21	cisplatin or carboplatin+gemcitabine + Tislelizumab	觸夢淵窪獵齋遞膚製築(鏇衊齋憲壓顧願鬱製鏇) = 襯鬱窪醖獵衊顧餘鬱鏇廠繭衊網夢鹹製觸廠蓋 (鬱糧範鹹艱網繭醖觸淵 )	积极	2024-01-25